The diagnosis of polycythaemia vera (PV) has been established upon sets of clinical criteria, which require the presence of absolute erythrocytosis (AE). The most recent clinical criteria for PV, published by the World Health Organization (WHO) in 2001, also required AE, and stated that the measured red cell mass (RCM) could be replaced by a surrogate marker for AE; a haemoglobin (Hb) value of >18.5 g/dl in males and >16.5 g/dl in females. The present study evaluated the potential of venous haematocrit (Hct) and Hb values as possible surrogate markers for AE in a series of 77 consecutive patients with PV and 66 patients with apparent polycythaemia (AP), in all of whom the RCM had been previously determined. In only 35% of the male PV patients would Hb values >18.5 g/dl indicate the presence of AE. Conversely, 14% of male AP patients would be misdiagnosed as having AE. A Hb > 16.5 g/dl would predict the presence of AE in 63% of the female PV patients, but 35% of female AP cases would be misdiagnosed as having AE. However, when the Hct was > or =0.60 an AE was always present, and this was true for both male and female subjects.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1365-2141.2005.05517.x | DOI Listing |
Expert Rev Mol Diagn
March 2025
Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Background: The incidence of colorectal cancer (CRC) is rapidly increasing, and early detection plays a crucial role in improving the prognosis and survival rates of patients. This study aimed to assess the diagnostic ability of combined SDC2-KCNQ5-IKZF1 methylation levels in plasma for CRC detection.
Methods: A total of 92 patients were recruited from the Department of General Surgery at the Second Hospital of Hebei Medical University, including 56 CRC patients, 22 polyp and adenoma patients, and 14 healthy controls.
Background: This study aimed to investigate the clinical value of the serum albumin-to-globulin ratio (AGR) in diagnosing multiple myeloma (MM) and its differential diagnosis from other conditions such as liver and kidney diseases to provide scientific evidence for clinical decision-making.
Methods: A total of 52 newly-diagnosed MM patients from Tongxiang First People's Hospital between January 2020 and June 2024 were selected as the study group. Additionally, 56 patients newly diagnosed with liver disease and 58 patients newly diagnosed with kidney disease during the same period were used as disease control groups, along with 54 healthy individuals serving as the normal control group.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!